Suspended PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT05001854

Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline Septic Shock Patients (FLUDROSEPSIS)

Evaluation of the Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline in Septic Shock Patients

Sponsor: H.A.C. PHARMA

Conditions Septic Shock

Interventions Fludrocortisone Placebo

Updated 4 times since 2021 Last updated: Nov 15, 2023 Started: Mar 31, 2022 Primary completion: Jun 30, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

study suspended until new therapeutic units are available

Listed as NCT05001854, this PHASE2/PHASE3 trial focuses on Septic Shock and remains suspended. Sponsored by H.A.C. PHARMA, it has been updated 4 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Suspended PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2023 — Jul 2024 [monthly]

Suspended PHASE2_PHASE3

Status: Not Yet Recruiting → Suspended
Sep 2021 — Dec 2023 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H.A.C. PHARMA
Rennes University Hospital

Data source: Rennes University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rennes, France